top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hCD28 mice
Strain Name
C57BL/6N-Cd28tm1(CD28)Bcgen/Bcgen
Common Name  B-hCD28 mice
Background C57BL/6N Catalog number  110007
Related Genes 
CD28 (Cluster of Differentiation 28)
NCBI Gene ID
12487

This product ("B-hCD28 mice") and/or its use, is protected by the following patents:

US Patent No.11350614

CN Patent No.109136261


mRNA expression analysis


from clipboard

Strain specific analysis of CD28 gene expression in WT and B-hCD28 mice by RT-PCR. Mouse Cd28 mRNA was detectable in splenocytes of wild-type (+/+) and heterozygous (H/+) mice. Human CD28 mRNA was detectable only in H/+, but not in +/+ mice.


Protein expression analysis

from clipboard

Strain specific CD28 expression analysis in homozygous B-hCD28 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hCD28 mice (H/H) stimulated with or without anti-CD3ε antibody in vivo, and analyzed by flow cytometry with species-specific anti-CD28 antibodies. Mouse CD28 was detectable in wild-type C57BL/6 mice. Human CD28 was exclusively detectable in homozygous B-hCD28 mice but not in wild-type C57BL/6 mice.


Analysis of spleen leukocytes cell subpopulations in B-hCD28 mice

from clipboard

from clipboard


Analysis of spleen leukocyte subpopulations by FACS.Splenocytes were isolated from female C57BL/6 and B-hCD28 mice (n=3, 6 week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, NK, Monocyte, DC and macrophage cells in homozygous B-hCD28 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hCD28 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen.

Analysis of spleen T cell subpopulations in B-hCD28 mice


from clipboard


Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hCD28 mice (n=3, 6 week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hCD28 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hCD28 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in spleen. Values are expressed as mean ± SEM.


Analysis of blood leukocytes cell subpopulations in B-hCD28 mice


from clipboard

from clipboard

Analysis of blood leukocyte subpopulations by FACS.Blood were isolated from female C57BL/6 and B-hCD28 mice (n=3, 6 week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, NK, Monocyte, DC and macrophage cells in homozygous B-hCD28 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hCD28 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in blood.


Analysis of blood T cell subpopulations in B-hCD28 mice

from clipboard

Analysis of blood T cell subpopulations by FACS.Leukocytes were isolated from female C57BL/6 and B-hCD28 mice (n=3, 6 week-old). Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hCD28 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hCD28 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in blood. Values are expressed as mean ± SEM.


Analysis of T cell activation stimulated with anti-CD3 and anti-CD28 antibody in vitro

from clipboard


Analysis of T cell activation stimulated with anti-CD3 and anti-CD28 antibody in vitro. Homozygous B-hCD28 mice were treated with anti-mCD3e antibody and anti-mCD28 antibody or anti-hCD28 antibody as indicated on the graph (female, 6 week-old, n=3). T cells were analyzed at 24, 48 and 72 hours after treatment. Anti-mCD28 antibody resulted in an increased activation of T cells in WT mice, and anti-hCD28 antibody resulted in an increased activation of T cells in B-hCD28 mice. Values are expressed as mean ± SEM.

Analysis of T cell proliferation stimulated with anti-CD3 and anti-CD28 antibody in vitro


from clipboard

Analysis of T cell proliferaion stimulated with anti-CD3 and anti-CD28 antibody in vitro. Homozygous B-hCD28 mice were treated with anti-mCD3e antibody and anti-mCD28 antibody or anti-hCD28 antibody as indicated on the graph (female, 6 week-old, n=3). T cells were analyzed at 48 and 72 hours after treatment. Anti-mCD28 antibody resulted in an increased proliferation of T cells in WT mice, and anti-hCD28 antibody resulted in an increased proliferation of T cells in B-hCD28 mice. Values are expressed as mean ± SEM.


Anti human CD28 therapies led to changed cytokine profile in B-hCD28 mice

from clipboard

Anti-human CD28 therapies led to changed cytokine profile in B-hCD28 mice. Homozygous B-hCD28 mice were treated with anti-mCD3e antibody and anti-mCD28 antibody or anti-hCD28 antibody as indicated on the graph (female, 6 week-old, n=3). Serum cytokine levels were analyzed at 24, 48 and 72 hours after treatment. Anti-mCD28 antibody resulted in an increase of IFN-γ, IL-2 in WT mice, and anti-hCD28 antibody resulted in an increase of IFN-γ, IL-2 in B-hCD28 mice. Values are expressed as mean ± SEM.


hPD-L1 recombination protein immunization led to unchanged IgG profile in B-hCD28 mice

from clipboard


hPD-L1 recombination protein immunization led to unchanged IgG profile in B-hCD28 mice. C57BL/6 and B-hCD28 mice (female, 6 week-old, n=5) were immunized by hPD-L1 recombination protein with CFA. No difference was found in serum antibody titer in WT and hCD28 mice, indicating that the B7-1/CD28 co-stimulating signaling pathway was normal in B-hCD28 mice. 


In vivo efficacy of anti-human CD28 antibody

from clipboard

Antitumor activity of anti-human CD28 antibody in B-hCD28 mice. (A) Anti-human CD28 antibody inhibited MC38 tumor growth in B-hCD28 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCD28 mice (female, 6-7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human CD28 antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, two anti-human CD28 antibody were efficacious in controlling tumor growth in B-hCD28 mice, demonstrating that the B-hCD28 mice provide a powerful preclinical model for in vivo evaluation of anti-human CD28 antibody. Values are expressed as mean ± SEM.


In vivo efficacy of anti-human PD-L1xCD28 bispecific antibody

from clipboard


Antitumor activity of anti-PD-L1 and anti-CD28 (PD-L1xCD28) bispecific antibody (BsAb) in B-hCD28 mice.Murine colon cancer B-hPD-L1 MC38 plus cells were subcutaneously implanted into homozygous B-hCD28 mice (female, 7-8 week-old, n=10). Mice were grouped when tumor volume reached approximately 200 mm3, at which time they were treated with anti-human PD-L1xCD28 BsAbs provided by the client. (A) anti-human PD-L1xCD28 BsAbs inhibited B-hPD-L1 MC38 plus cells tumor growth in B-hCD28 mice. (B) Body weight changes during treatment. As shown in panel A, anti-human PD-L1xCD28 BsAbs were efficacious in controlling tumor growth in B-hCD28 mice, demonstrating that the B-hCD28 mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-L1xCD28 BsAbs. Values are expressed as mean ± SEM.